Introduction
============

Osteoarthritis is one of the leading causes of disability in the elderly. The changes in the lubricating properties of synovial fluid lead to significant pain and loss of function. Viscosupplementation, the injection of hyaluronic acid (HA) into the joints, improves the biochemical properties of synovial fluid into osteoarthritis joints. The clinical effect is pain relief and disease modifying activity ([@b4]; [@b23]).

Although there are many nonsurgical therapies available for the treatment of pain associated with osteoarthritis (OA), their long-term use and safety have not been systematically followed. Intra-articular (IA) hyaluronan therapy has been used in the treatment of symptoms associated with OA of the knee with a very favorable safety profile ([@b22]). In this connection, the physiological and pharmacological characteristics of HA have recently been reviewed. The high concentration of HA in spinal fluid (SF) is essential for normal joint function. The altered properties of the synovial fluid in OA, the decrease in molecular size and concentration of HA leads to reduced rheologic properties, which affect the lubrication and protection mechanism of action of IA hyaluronan and is probably more complex than previously thought ([@b17]).

The hypothesis that HA could bind to specific receptors is now widely accepted. The cluster determinant 44 (CD44), the intracellular adhesion molecule-1 (ICAM-1) and the receptor for hyaluronate-mediated motility (RHAMM) expressed in many cells, are some of those implicated in the process ([@b13]; [@b27]). The binding of HA with its specific receptors has been reported to trigger various intracellular signal events such as cytokine release and stimulation of cell cycle proteins. The consequences of these interactions is to stimulate cell functional activities such as cell migration and proliferation (Cao et al 2004).

More than ten years have passed since the original explanation by [@b4] that the favorable effects of IA HA therapy in OA was related only to the restoration of SF rheological properties ([@b12]). Many subsequent studies have supported that IA HA therapy is a symptom-modifying approach that has been found to be safe and effective for reducing pain due to OA of the knee and furthermore may also significantly decrease the rate of deterioration of joint structure. This statement stems from different evidences. rst of all, the complex biochemical effects of HAs in the synovium and extracellular matrix of the articular cartilage, including interactions between exogenously administered HA and articular cartilage, subchondral bone, matrix proteoglycans, and collagens. In the second place, the effects of HA administration in animal models of OA, including total or partial meniscectomy and anterior cruciate ligament transectomy. Thirdly, the results of clinical trials using one HA, Hyalgan (sodium hyaluronate, molecular weight 500--730 kDa) that evaluated structural outcomes, such as joint-space width, chondrocyte density and vitality, and arthroscopic evaluation of chondropathy. Localized severe acute inflammatory reactions reported with repeated treatment in some patients are not a class effect but may be linked to physicochemical characteristics of hylan-based treatment ([@b2]; [@b22]; [@b12]).

Studies on the effects of HAs of different molecular weight (MW) on specific receptors have shown that the results can vary depending on the size of the HA molecules used. For example low MH HA fragments generated during joint inflammation may promote chemokine gene expression by macrophages. [@b21] noticed that HA preparation of MW 0.2 × 106 Da was more effective in maintaining the survaival of blood eosinophils than HA with an MW of 3 × 106 −6 × 106 Da, proposing that the effect derived from the increased expression of granulocyte macrophage colony-stimulating factor after CD44 activation ([@b21]).

Different HA products
=====================

Presently, there are several different HA products available for injection. However, the source of hyaluronic acid varies. Some products are extracted from rooster combs but a contraindication to treatment would be an allergy to eggs or chicken.

Hyaluronic acid is available in a variety of products with different molecular weight ranging from 500 KD to more than 90 millions D ([Table 1](#tbl1){ref-type="table"}). Hylans are cross-linked hyaluronic acids, which gives them a higher molecular weight and increased elastoviscous properties.

###### 

Molecular weights of hyaluronic acid (HA) products

  Trade name           Molecular weight   Source                            Mg/ml
  -------------------- ------------------ --------------------------------- --------------
  Hyalgan              500--730 KDa       HA extracted from rooster combs   20 mg/2 ml
  Hyalubrix ≷          1500 KDa           Fermentative HA                   30 mg/2 ml
  Artz (Supartz)       800--1170 KDa      HA extracted from rooster combs   25 mg/2.5 ml
  Synovial (Jointex)   800--1200 KDa HA   Fermentative HA                   16 mg/ml
  Synvisc              6000 KDa           HA extracted from rooster combs   16 mg/2 ml
  Durolane             90 millions Da     Synthetic HA                      20 mg/ 3 ml
  Euflexxa             2.400--3.600 kDa   Fermentative HA                   20 mg/2 ml

HA products in the intra-articular treatment of knee OA
=======================================================

The first studies on the use of HA in human knee OA were carried out in the 1970s by [@b26] and [@b24]. In 1974, Peyron injected 1, 2, or 3 ml of HA (Healon) in 23 knees and obtained positive responses in pain and function in 74% of patients. The treatment with two injections of 2 ml HA each appeared to have the best outcome.

Recent papers have reviewed clinical trials published in the last years using different HA preparation and the results of these trials are summarized in [Table 2](#tbl2){ref-type="table"}.

###### 

Recent clinical trials using HA

  Author / Year   N trials                                                                                                                                                                                          Intervention                                                                                                                                                                                                                   Conclusions
  --------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Lo et al 2004   22 selected trials                                                                                                                                                                                Hyalgan, Synvisc, Artzal, Suplasyn, BioHy, Orthovisc                                                                                                                                                                           Measurable effect when compared with placebo. Highest-molecular-weight HAs may be more. Heterogeneity of these studies limits definitive conclusions.
  [@b1]           ve case series 13 RCTs                                                                                                                                                                            Synvisc low-molecular-weight HA                                                                                                                                                                                                High-molecular-weight HAs effective. Conflicting results with low-molecular-weight. Slower onset of action than intra-articular steroids, but the effect last longer.
  [@b30]          Twenty blinded randomized controlled trials                                                                                                                                                       Hyaluronic acid versus placebo                                                                                                                                                                                                 Therapeutic efficacy and safety
  [@b3]           Potential use in the treatment of inflammatory arthropathies (eg, acute joint trauma and fractures)                                                                                               Hyaluronans                                                                                                                                                                                                                    Trials limited in design and patient number. Moderate results. Controlled clinical trials are warranted.
  [@b12]          A review on a Medline search through June 2004                                                                                                                                                    Hyalgan, Supartz, Synvisc                                                                                                                                                                                                      In addition to relieving the symptoms, HAs also modify the structure of the diseased joint and the rate of OA disease progression.
  [@b2]           Twenty-two trials                                                                                                                                                                                 Hyaluronic acid                                                                                                                                                                                                                The data available did not allow an appropriate assessment of any end point. Adverse events occurred slightly more often.
  [@b5]           Thirty-seven trials included comparisons of hyaluronan/hylan and placebo, nine trials included comparisons of intra-articular corticosteroids, and five trials included comparisons of (NSAIDs)   Adant, Arthrum H, Artz (Artzal, Supartz), BioHy (Arthrease), Durolane, Fermathron, Go-on, Hyalgan, Hylan G-F 20 (Synvisc Hylan G-F 20), NRD-101, Orthovisc, Ostenil, Replasyn, SLM-10, Suplasyn, Synject and Zeel compositum   The effects against 'placebo' controls generally supported the efficacy. Delayed effects on pain and function. Comparable efficacy against NSAIDs and longer-term benefits against IA corticosteroids. Few adverse events were reported.
  [@b22]          Databases were searched using the terms hyaluronan, sodium hyaluronate, hyaluronic acid, hylan, hylan G-F 20                                                                                      Hyaluronan, sodium hyaluronate, hyaluronic acid, hylan, hylan G-F 20                                                                                                                                                           Hyaluronans are safe and effective in the treatment of pain. Sodium hyaluronate decrease the rate of deterioration of joint structure

**Abbreviations:** IA, intra articular; RCT, randomized controlled trials; HA, hyaluronic acid; OA, osteoarthritis.

Data support the benefit and safety of repeated treatment with IA HA. Many trials indicate that sodium hyaluronate (molecular weight \[MW\] 500--730 kDa) is well tolerated and as effective after multiple courses of treatment as it is after a single course ([@b22]). Other data state that viscosupplementation is an effective treatment for patients with knee OA who have ongoing pain or are unable to tolerate conservative treatment or joint replacement.

Viscosupplementation appears to have a slower onset of action than intra-articular steroids, but the effect seems to last longer ([@b30]).

HA not only relieves the symptoms of OA but also modifies the structure of the diseased joint and the rate of OA disease progression, at least early in the evolution of the disease process ([@b21]).

Based on the aforementioned analyses, viscosupplementation is an effective treatment for OA of the knee with beneficial effects on pain, function and patient global assessment at different post injection periods but especially at the 5 to 13 week post injection period with a dramatic effect on the reduction of NSAIDs monthly consumption.

However, there are few randomized head-to-head comparisons of different viscosupplements and readers should be cautious, therefore, in drawing conclusions regarding the relative value of different products.

In some analyses, viscosupplements were comparable in efficacy to systemic forms of treatment, with more local reactions but fewer systemic adverse events. In other analyses HA products had more prolonged effects than IA corticosteroids. Overall, the aforementioned analyses support the use of the HA class of products in the treatment of knee OA ([@b16]). In one systematic review, IA HA has not been proven clinically effective and may be associated with minimal and transient risk of adverse events ([@b2]).

At present no case of septic arthritis has been reported in any clinical trial. Most adverse events are minor and transient at the injection site. Painful post-injection reaction occurred in 1%--2% of patients, the pain did not last more than 72 hours. Systemic allergic reactions due to individual hypersensitivity were rarely recorded. Therefore viscosupplementation seems to be an efficacious and safe treatment.

The heterogeneity of these studies limits definitive conclusions on different treatment regimen with diverse molecular weight HA but in our opinion we think that the different HA products act with the same class effect ([@b3]).

Furthermore preliminary data indicate a potential use for hyaluronans in the treatment of inflammatory arthropathies (eg, acute joint trauma and fractures) that require long periods of immobilization, and in tissue engineering for chondral defects. Although the trials that have investigated the use of hyaluronan therapy for the management of traumatic and degenerative musculoskeletal disorders seen in sports medicine have limitations in design and patient number, the results have been promising and suggest that larger controlled clinical trials are warranted ([@b24]).

HA products in the intra-articular treatment of hip OA
======================================================

Few data exists in literature about the viscosupplementation of hip OA in spite of it is the second most common site of the disease after the knee ([@b23]; [@b22]). One of the limiting factors for this practice might be related to the injection procedure. The intra-articular injection of the hip is not as easy as for the knee, mainly for anatomical features of the joint and the proximity of "sensitive" structures such as the femoral artery and nerves. Even though hip injection may be performed "blindly", failure rate is nevertheless significant ([@b15]) and when using a slow absorbing viscosupplement like hyaluronan, the potential local complications may jeopardize the therapeutic benefit ([@b14]). For such reasons, it has been suggested to perform intra-articular injection of the hip under radiological or ultrasound control. Although several ultrasound guidance techniques were available ([@b25]), we developed a personal one using an antero-superior approach ([@b18]).

Since no single or double blind randomized controlled trials have yet been published, we analyzed all the available trials on MEDLINE to assess viscosupplementation for the treatment of hip OA ([Table 3](#tbl3){ref-type="table"}).

###### 

Vscosupplementation studies for the treatment of hip osteoarthritis

  Author year   HA                   Nr of pts.   Outcome measures   Months of follow-up   Nr.of injections
  ------------- -------------------- ------------ ------------------ --------------------- ------------------
  [@b7]         Hyalgan              44           P/GA/NSAIDs        6                     3--5
  [@b8]         Synvisc              22           LI                 1--6                  1--2
  [@b11]        Synvisc              57           P/W/GA             3--6                  1--2
  [@b29]        Synvisc              22           P/AAOS/LLCSS       12                    3
  [@b18]        Hyalgan              28           P/LI/NSAIDs        NG                    1--3
  [@b9]         Synvisc              14           P/LI/15 mWT        3                     3
  [@b6]         Durolane             31           W/GA               3                     1
  [@b19]        Synvisc              26           P/LI/NSAIDs        12                    1--2
  [@b28]        Synvisc vs Ostenil   25 vs 18     P/W/LI             6                     3
  [@b20]        Synvisc              36           P/W/NSAIDs         18                    1--2

**Abbreviations:** P, pain; GA, global assessment; 15 mWT, 15-meter walking time; NSAIDs, NSAIDs consumption; LI, Lequesne index; W, Womac index; AAOS, American Academy of Orthopaedic Surgeons; LLCSS, Lower Limb Core Scale Score.

The efficacy data underlines significant improvement in pain and function as has been shown in the knee OA studies despite the small size of the sample. The short period of observation has not seen a change in the natural history of the disease. In order to confirm these promising data, large scale double blind controlled studies must be carried out.

Conclusions
===========

The ongoing studies continue to further our understanding of the fundamental mechanisms that likely underlie the therapeutic benefits of this treatment. The meta-analysis in progress are further establishing a role for viscosupplementation in ameliorating the symptoms of knee and hip osteoarthritis. At the moment it is clear that viscosupplementation is more efficacious in the initial and intermediate stages of OA more than at an advanced stages and that this therapy is exceptionally safe compared with other OA treatments.

Despite recent progress, many unresolved issues require further study. These include determining the cost-effectiveness of viscosupplementation, exploring the therapeutic effectiveness and safety, clearly defining the relation between molecular weight and the clinical effectiveness of the various hyaluronan products, establishing optimal dosing regiments, evaluating efficacy in different OA populations, determining how to best incorporate viscosupplementation into the evolving OA treatments algorithms, exploring the potential for treatment of OA joints other than the knee, as already shown for the hip, and assessing potential synergistic or additive effects with other modalities such NSAIDs and SYSADOA.

It is encouraging that hyaluronan-based therapy is proving to be safe and effective for many patients with symptomatic hip and knee OA despite the fact that many unresolved issues requiring further study remain. If hyaluronan derivatives are eventually proven to have clear disease-modifying effects, it may then be reasonable to consider their use early in cartilage injury or disease, before the onset of syntomatic OA.

Additional well-designed randomized controlled trials with high methodological quality are needed to resolve the continued uncertainty about the therapeutic effects of different types of hyaluronic acid products on osteoarthritis in various clinical situations and patient populations ([@b30]).

At the moment the Arthritis Foundation believes that while more studies are needed to determine the long-term results of such treatments, HA provides an option for people with knee OA who have not responded well to drug treatments or exercise and physical therapy. It also may be appropriate for those who may be at increased risk for upper gastrointestinal (GI) complications, such as patients who: are over 65 years old; are taking oral corticosteroids and/or anticoagulants; have a history of peptic ulcer disease or upper GI bleeding; are smokers; and consume high volumes of alcohol. HA also may be considered in patients with kidney failure.
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